NO20052223L - Tiazolforbindelser for behandling av neurodegenerative forstyrrelser - Google Patents
Tiazolforbindelser for behandling av neurodegenerative forstyrrelserInfo
- Publication number
- NO20052223L NO20052223L NO20052223A NO20052223A NO20052223L NO 20052223 L NO20052223 L NO 20052223L NO 20052223 A NO20052223 A NO 20052223A NO 20052223 A NO20052223 A NO 20052223A NO 20052223 L NO20052223 L NO 20052223L
- Authority
- NO
- Norway
- Prior art keywords
- treatment
- neurodegenerative disorders
- thiazole compounds
- compounds
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41740002P | 2002-10-09 | 2002-10-09 | |
| US46320903A | 2003-06-17 | 2003-06-17 | |
| PCT/IB2003/004330 WO2004033439A1 (en) | 2002-10-09 | 2003-09-29 | Thiazole compounds for the treatment of neurodegenerative disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20052223D0 NO20052223D0 (no) | 2005-05-06 |
| NO20052223L true NO20052223L (no) | 2005-07-04 |
Family
ID=35306299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20052223A NO20052223L (no) | 2002-10-09 | 2005-05-06 | Tiazolforbindelser for behandling av neurodegenerative forstyrrelser |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US20040152747A1 (nl) |
| EP (1) | EP1551815A1 (nl) |
| JP (1) | JP2006504796A (nl) |
| KR (1) | KR20050070046A (nl) |
| CN (1) | CN1688557A (nl) |
| AP (1) | AP2005003274A0 (nl) |
| AR (1) | AR043051A1 (nl) |
| AU (1) | AU2003265068A1 (nl) |
| BR (1) | BR0314611A (nl) |
| CA (1) | CA2501803A1 (nl) |
| CO (1) | CO5550435A2 (nl) |
| CR (1) | CR7785A (nl) |
| EC (1) | ECSP055719A (nl) |
| GT (1) | GT200300219A (nl) |
| IS (1) | IS7738A (nl) |
| MA (1) | MA27451A1 (nl) |
| MX (1) | MXPA05002420A (nl) |
| NL (1) | NL1024499C2 (nl) |
| NO (1) | NO20052223L (nl) |
| OA (1) | OA12937A (nl) |
| PA (1) | PA8585001A1 (nl) |
| PE (1) | PE20040640A1 (nl) |
| PL (1) | PL376171A1 (nl) |
| TN (1) | TNSN05104A1 (nl) |
| TW (1) | TW200420550A (nl) |
| UY (1) | UY28011A1 (nl) |
| WO (1) | WO2004033439A1 (nl) |
| ZA (1) | ZA200502841B (nl) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2842523A1 (fr) * | 2002-07-17 | 2004-01-23 | Sanofi Synthelabo | Derives d'acylaminothiazole, leur preparation et leur application en therapeutique |
| JP2006525990A (ja) * | 2003-05-12 | 2006-11-16 | ファイザー・プロダクツ・インク | 神経変性障害の処置のためのイソオキサゾール化合物およびイソチアゾール化合物 |
| MXPA06001480A (es) * | 2003-08-06 | 2006-05-15 | Pfizer Prod Inc | Compuestos de oxazol para el tratamiento de trastornos neurodegenerativos. |
| FR2865206B1 (fr) * | 2004-01-16 | 2009-02-06 | Sanofi Synthelabo | Derives d'acylaminothiazole, leur preparation et leur application en therapeutique |
| FR2873370B1 (fr) * | 2004-07-22 | 2006-10-20 | Sanofi Synthelabo | Derives d'acylaminothiazole, leur preparation et leur application en therapeutique |
| WO2005073226A1 (fr) * | 2004-01-16 | 2005-08-11 | Sanofi-Aventis | Derives d’acylaminothiazole, leur preparation et leur application en therapeutique |
| FR2865207B1 (fr) * | 2004-01-16 | 2008-10-17 | Sanofi Synthelabo | Derives d'acylaminothiazole, leur preparation et leur application en therapeutique |
| DK1709018T3 (da) * | 2004-01-16 | 2011-11-14 | Sanofi Sa | Acylaminothiazolderivater og anvendelse deraf som beta-amyloid-hæmmere |
| FR2873374B1 (fr) * | 2004-07-22 | 2006-10-20 | Sanofi Synthelabo | Derives d'acylaminothiazole, leur preparation et leur application en therapeutique |
| DE602005007717D1 (de) * | 2004-03-23 | 2008-08-07 | Pfizer Prod Inc | Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen |
| US7384968B2 (en) * | 2004-04-01 | 2008-06-10 | Pfizer Inc. | Thiazole-amine compounds for the treatment of neurodegenerative disorders |
| US7220865B2 (en) * | 2004-04-01 | 2007-05-22 | Pfizer Inc | Isoxazole-and isothiazole-amine compounds for the treatment of neurodegenerative disorders |
| MX2007001727A (es) | 2004-08-13 | 2007-04-20 | Genentech Inc | Compuestos a base de 2-amido-tiazol que exhiben actividad inhibidora de enzima que utiliza atp y composiciones y usos de los mismos. |
| US7888379B2 (en) * | 2005-05-24 | 2011-02-15 | Merck Serono Sa | Thiazole derivatives and use thereof |
| FR2887879B1 (fr) * | 2005-07-01 | 2008-09-26 | Trophos Sa | Nouveaux composes chimiques et leurs utilisations comme medicament,particulierement dans le traitement des maladies neurodegeneratives |
| WO2007034326A2 (en) * | 2005-09-22 | 2007-03-29 | Pfizer Products Inc. | Imidazole compounds for the treatment of neurological disorders |
| US8105581B2 (en) | 2005-12-01 | 2012-01-31 | The Scripps Research Institute | Compositions and methods for inducing neuronal differentiation |
| EP1981884B1 (en) * | 2006-01-18 | 2012-06-13 | Amgen, Inc | Thiazole compounds as protein kinase b (pkb) inhibitors |
| ATE538108T1 (de) * | 2006-11-05 | 2012-01-15 | Max Planck Gesellschaft | Thiazolhydrazide und deren verwendung zur behandlung von neurodegenerativen krankheiten |
| GB0701426D0 (en) * | 2007-01-25 | 2007-03-07 | Univ Sheffield | Compounds and their use |
| US7919504B2 (en) * | 2007-07-17 | 2011-04-05 | Amgen Inc. | Thiadiazole modulators of PKB |
| JP2010533715A (ja) | 2007-07-17 | 2010-10-28 | アムジエン・インコーポレーテツド | 複素環系ｐｋｂ調節剤 |
| CA2731097A1 (en) * | 2008-07-15 | 2010-01-21 | Novartis Ag | Organic compounds |
| US8889670B2 (en) | 2009-02-18 | 2014-11-18 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds which modulate the CB2 receptor |
| WO2010126002A1 (ja) * | 2009-04-28 | 2010-11-04 | 塩野義製薬株式会社 | ヘテロ環スルホンアミド化合物を含有する医薬 |
| US8299103B2 (en) * | 2009-06-15 | 2012-10-30 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the CB2 receptor |
| JP2013517271A (ja) | 2010-01-15 | 2013-05-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｂ２受容体を調節する化合物 |
| EP2595959B1 (en) | 2010-07-22 | 2015-11-04 | Boehringer Ingelheim International GmbH | Sulfonyl compounds which modulate the cb2 receptor |
| CN102351854B (zh) * | 2011-07-29 | 2014-06-04 | 华中科技大学 | 氨基噻唑衍生物及制备方法和医药用途 |
| CA2899088C (en) * | 2013-03-14 | 2022-12-20 | Merck Patent Gmbh | Thiazole and oxazole compounds as glycosidase inhibitors |
| EP2803668A1 (en) | 2013-05-17 | 2014-11-19 | Boehringer Ingelheim International Gmbh | Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
| CN103408541B (zh) * | 2013-07-16 | 2015-04-01 | 浙江医药高等专科学校 | 吲哚取代的噻唑并环己烷类化合物、及其抗肿瘤用途 |
| CN103435573B (zh) * | 2013-07-16 | 2015-04-01 | 浙江医药高等专科学校 | 苄基取代的噻唑并环己烷类化合物、其制备方法和用途 |
| GB201401886D0 (en) * | 2014-02-04 | 2014-03-19 | Lytix Biopharma As | Neurodegenerative therapies |
| US11274100B2 (en) | 2017-06-21 | 2022-03-15 | Daiichi Sankyo Company, Limited | EP300/CREBBP inhibitor |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06508135A (ja) * | 1991-05-28 | 1994-09-14 | メルク エンド カンパニー インコーポレーテッド | 抗変性活性剤としての置換ｎ−カルボキシアルキルペプチジル誘導体 |
| CO5021134A1 (es) * | 1998-05-01 | 2001-03-27 | Abbott Lab | Inhibidores beta-aminoacidos substituidos de aminopeptida- sa-2 metionina |
| SK16282000A3 (sk) * | 1998-05-01 | 2001-05-10 | Abbott Laboratories | Substituované beta-aminokyselinové inhibítory metionínaminopeptidázy-2 |
| WO2000024392A1 (fr) * | 1998-10-26 | 2000-05-04 | Sumitomo Pharmaceuticals Company, Limited | Inhibiteur de la formation de beta-amyloide |
| AR039059A1 (es) * | 2001-08-06 | 2005-02-09 | Sanofi Aventis | Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios |
| FR2842523A1 (fr) * | 2002-07-17 | 2004-01-23 | Sanofi Synthelabo | Derives d'acylaminothiazole, leur preparation et leur application en therapeutique |
-
2003
- 2003-09-29 BR BR0314611-1A patent/BR0314611A/pt not_active IP Right Cessation
- 2003-09-29 OA OA1200500098A patent/OA12937A/en unknown
- 2003-09-29 AU AU2003265068A patent/AU2003265068A1/en not_active Abandoned
- 2003-09-29 CA CA002501803A patent/CA2501803A1/en not_active Abandoned
- 2003-09-29 JP JP2005501002A patent/JP2006504796A/ja active Pending
- 2003-09-29 AP AP2005003274A patent/AP2005003274A0/xx unknown
- 2003-09-29 WO PCT/IB2003/004330 patent/WO2004033439A1/en active Application Filing
- 2003-09-29 KR KR1020057006168A patent/KR20050070046A/ko not_active Application Discontinuation
- 2003-09-29 CN CNA038240106A patent/CN1688557A/zh active Pending
- 2003-09-29 EP EP03807933A patent/EP1551815A1/en not_active Withdrawn
- 2003-09-29 MX MXPA05002420A patent/MXPA05002420A/es not_active Application Discontinuation
- 2003-09-29 PL PL03376171A patent/PL376171A1/xx not_active Application Discontinuation
- 2003-10-03 TW TW092127495A patent/TW200420550A/zh unknown
- 2003-10-07 PE PE2003001021A patent/PE20040640A1/es not_active Application Discontinuation
- 2003-10-08 PA PA20038585001A patent/PA8585001A1/es unknown
- 2003-10-08 US US10/682,686 patent/US20040152747A1/en not_active Abandoned
- 2003-10-08 AR ARP030103662A patent/AR043051A1/es unknown
- 2003-10-09 GT GT200300219A patent/GT200300219A/es unknown
- 2003-10-09 NL NL1024499A patent/NL1024499C2/nl not_active IP Right Cessation
- 2003-10-09 UY UY28011A patent/UY28011A1/es not_active Application Discontinuation
-
2005
- 2005-03-10 IS IS7738A patent/IS7738A/is unknown
- 2005-04-07 CR CR7785A patent/CR7785A/es not_active Application Discontinuation
- 2005-04-07 EC EC2005005719A patent/ECSP055719A/es unknown
- 2005-04-08 TN TNP2005000104A patent/TNSN05104A1/fr unknown
- 2005-04-08 CO CO05031337A patent/CO5550435A2/es not_active Application Discontinuation
- 2005-04-08 MA MA28206A patent/MA27451A1/fr unknown
- 2005-05-06 NO NO20052223A patent/NO20052223L/no unknown
-
2006
- 2006-01-17 ZA ZA200502841A patent/ZA200502841B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GT200300219A (es) | 2004-05-18 |
| UY28011A1 (es) | 2004-04-30 |
| ZA200502841B (en) | 2006-03-29 |
| CA2501803A1 (en) | 2004-04-22 |
| US20040152747A1 (en) | 2004-08-05 |
| JP2006504796A (ja) | 2006-02-09 |
| MXPA05002420A (es) | 2005-10-05 |
| IS7738A (is) | 2005-03-10 |
| PA8585001A1 (es) | 2004-12-16 |
| CR7785A (es) | 2005-07-08 |
| PE20040640A1 (es) | 2004-09-15 |
| NL1024499C2 (nl) | 2004-10-13 |
| AU2003265068A1 (en) | 2004-05-04 |
| PL376171A1 (en) | 2005-12-27 |
| BR0314611A (pt) | 2005-07-26 |
| TW200420550A (en) | 2004-10-16 |
| OA12937A (en) | 2006-10-13 |
| NL1024499A1 (nl) | 2004-04-13 |
| ECSP055719A (es) | 2005-07-06 |
| EP1551815A1 (en) | 2005-07-13 |
| CO5550435A2 (es) | 2005-08-31 |
| AR043051A1 (es) | 2005-07-13 |
| MA27451A1 (fr) | 2005-07-01 |
| AP2005003274A0 (en) | 2005-06-30 |
| NO20052223D0 (no) | 2005-05-06 |
| WO2004033439A1 (en) | 2004-04-22 |
| CN1688557A (zh) | 2005-10-26 |
| KR20050070046A (ko) | 2005-07-05 |
| TNSN05104A1 (fr) | 2007-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20052223L (no) | Tiazolforbindelser for behandling av neurodegenerative forstyrrelser | |
| NO20064726L (no) | Imidazolforbindelser for behandling av neurodegenerative forstyrrelser | |
| CA2501799A1 (en) | Pyrazole compounds for treatment of neurodegenerative disorders | |
| NO20064989L (no) | Sulfonamidforbindelser for behandling av neurodegenerative lidelser | |
| NO20071719L (no) | Pyridylinhibitorer for "hedgehog"-signalisering | |
| DK2527315T3 (da) | Forbindelser, præparater og fremgangsmåder til behandling af amyloide sygdomme og synukleinopatier, såsom Alzheimers sygdom, type 2-diabetes og Parkinsons sygdom | |
| GB0318447D0 (en) | Therapeutic agents | |
| NO20045137L (no) | Diketohydrazinderivatforbindelser og legemidler inneholdende forbindelser som aktiv ingrediens | |
| CA2473070A1 (en) | Proline compounds as ns3-serine protease inhibitors for use in treatment of hepatites c virus infection | |
| MXPA05011150A (es) | 2-hidroxi-3-diaminoalcanos de benzamida. | |
| MXPA04003245A (es) | Hidroxipropilaminas. | |
| TW200505828A (en) | Substituted ureas and carbamates useful in the treatment of alzheimer's disease | |
| MXPA04002785A (es) | Aminas sustituidas para tratamiento de enfermedad de alzheimer. | |
| CA2534532A1 (en) | Compounds for the treatment of neurodegenerative disorders | |
| BR0316723A (pt) | Derivados de anilinopirazol úteis para o tratamento de diabetes | |
| ATE396986T1 (de) | Pyrimidylpyrrolderivate, die als kinaseinhibitoren wirken | |
| ATE371724T1 (de) | Behandlung neurodegenerativer krankheiten | |
| MXPA03011466A (es) | Macrociclos utiles en tratamiento de enfermedades de alzheimer. | |
| NO20060020L (no) | 3-fluorpiperidiner som NMDA/NR2B-antagonister | |
| MX2010002765A (es) | Derivado de 6-pirimidinil-pirimid-4-ona. | |
| NO20044530L (no) | Fremgangsmate for behandling av kognitive forstyrrelser | |
| DE602004010314D1 (de) | Behandlung von neurodegenerativen erkrankungen durch verwendung von degs-inhibitoren | |
| NO20081845L (no) | Imidazolforbindelser for behandling av neurologiske lidelser | |
| NO20044531L (no) | Imidazolinylmetyl-aralkylsulfonamider, blandinger omfattende slike, fremgangsmate for fremstilling av slike, slike forbindelser som medikament samt anvendelse av slike forbindelser for fremstilling av medikamenter for behandling av sykdom | |
| CA2534529A1 (en) | Oxazole compounds for the treatment of neurodegenerative disorders |